Advanced

Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression

Puchades, Maja; Nilsson, Carol L LU ; Emmett, Mark R; Aldape, Kenneth D; Ji, Yongjie; Lang, Frederick; Liu, Ta-Jen and Conrad, Charles A. (2007) In Journal of Proteome Research 6(2). p.75-869
Abstract

Global protein analysis of treated and untreated glioblastoma cell lines was performed. Proteomic analysis revealed the identity of proteins that were significantly modulated by the treatment with wild-type TP53 and the cytotoxic chemotherapy SN38. In particular, galectin-1 was found to be negatively regulated by transfection with TP53 and further down-regulated by SN38. Expression level changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell lines demonstrated very high levels of galectin-1, regardless if the cell lines contained mutant or wild-type TP53. High expression of galectin-1 in a human orthotopic murine tumor model was also detected by immunohistochemistry and revealed a consistent... (More)

Global protein analysis of treated and untreated glioblastoma cell lines was performed. Proteomic analysis revealed the identity of proteins that were significantly modulated by the treatment with wild-type TP53 and the cytotoxic chemotherapy SN38. In particular, galectin-1 was found to be negatively regulated by transfection with TP53 and further down-regulated by SN38. Expression level changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell lines demonstrated very high levels of galectin-1, regardless if the cell lines contained mutant or wild-type TP53. High expression of galectin-1 in a human orthotopic murine tumor model was also detected by immunohistochemistry and revealed a consistent pattern of preferential expression in peripheral or leading tumor edges. Further examination of galectin-1 expression through microarray analysis in tumor materials from patients confirmed galectin-1 as a valuable biomarker and possible therapeutic target. These results demonstrate the utility of using proteomic approaches to interrogate and identify potential useful targets for cancer therapy by evaluating specific tumor responses, either positive or negative, to various therapies.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
keywords
Animals, Antineoplastic Agents, Blotting, Western, Cell Division, Cell Line, Tumor, Cell Survival, Electrophoresis, Gel, Two-Dimensional, Galectin 1, Genetic Therapy, Glioblastoma, Humans, Mass Spectrometry, Neoplasm Transplantation, Proteomics, Transplantation, Heterologous, Tumor Suppressor Protein p53, Journal Article, Research Support, Non-U.S. Gov't
in
Journal of Proteome Research
volume
6
issue
2
pages
7 pages
publisher
The American Chemical Society
external identifiers
  • scopus:33847399649
ISSN
1535-3893
DOI
10.1021/pr060302l
language
English
LU publication?
no
id
ba4ba3a9-82c5-4aa6-822d-9497456414a9
date added to LUP
2017-05-16 10:33:14
date last changed
2017-05-21 05:01:37
@article{ba4ba3a9-82c5-4aa6-822d-9497456414a9,
  abstract     = {<p>Global protein analysis of treated and untreated glioblastoma cell lines was performed. Proteomic analysis revealed the identity of proteins that were significantly modulated by the treatment with wild-type TP53 and the cytotoxic chemotherapy SN38. In particular, galectin-1 was found to be negatively regulated by transfection with TP53 and further down-regulated by SN38. Expression level changes were confirmed by Western blot. Subsequent analysis of several high-grade glioma cell lines demonstrated very high levels of galectin-1, regardless if the cell lines contained mutant or wild-type TP53. High expression of galectin-1 in a human orthotopic murine tumor model was also detected by immunohistochemistry and revealed a consistent pattern of preferential expression in peripheral or leading tumor edges. Further examination of galectin-1 expression through microarray analysis in tumor materials from patients confirmed galectin-1 as a valuable biomarker and possible therapeutic target. These results demonstrate the utility of using proteomic approaches to interrogate and identify potential useful targets for cancer therapy by evaluating specific tumor responses, either positive or negative, to various therapies.</p>},
  author       = {Puchades, Maja and Nilsson, Carol L and Emmett, Mark R and Aldape, Kenneth D and Ji, Yongjie and Lang, Frederick and Liu, Ta-Jen and Conrad, Charles A.},
  issn         = {1535-3893},
  keyword      = {Animals,Antineoplastic Agents,Blotting, Western,Cell Division,Cell Line, Tumor,Cell Survival,Electrophoresis, Gel, Two-Dimensional,Galectin 1,Genetic Therapy,Glioblastoma,Humans,Mass Spectrometry,Neoplasm Transplantation,Proteomics,Transplantation, Heterologous,Tumor Suppressor Protein p53,Journal Article,Research Support, Non-U.S. Gov't},
  language     = {eng},
  number       = {2},
  pages        = {75--869},
  publisher    = {The American Chemical Society},
  series       = {Journal of Proteome Research},
  title        = {Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression},
  url          = {http://dx.doi.org/10.1021/pr060302l},
  volume       = {6},
  year         = {2007},
}